Diosmin
Diosmin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bruselix bruising | unapproved drug other | 2024-10-11 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 1 | 1 | 2 | 6 | 10 |
| Venous insufficiency | D014689 | — | — | — | — | 4 | 4 | 1 | 9 |
| Hemorrhoids | D006484 | EFO_0009552 | K64 | — | — | 1 | 1 | 3 | 5 |
| Thrombosis | D013927 | — | — | — | — | — | 1 | — | 1 |
| Venous thrombosis | D020246 | — | I82.40 | — | — | — | 1 | — | 1 |
| Postphlebitic syndrome | D011186 | — | I87.0 | — | — | — | 1 | — | 1 |
| Postthrombotic syndrome | D054070 | EFO_0007452 | I87.0 | — | — | — | 1 | — | 1 |
| Lymphedema | D008209 | — | Q82.0 | — | — | — | 1 | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 1 | — | 1 |
| Rectal fistula | D012003 | — | K60.3 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | 1 | — | 3 | 4 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | 1 | — | 3 | 4 |
| Alcoholic fatty liver | D005235 | — | K70.0 | — | — | 1 | — | 3 | 4 |
| Ulcer | D014456 | MPATH_579 | — | — | — | 2 | — | 2 | 4 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | 1 | — | 1 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | 1 | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | 1 | 2 |
| Infertility | D007246 | EFO_0000545 | — | — | 1 | 1 | — | 1 | 2 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | — | 1 | 1 | — | 1 | 2 |
| Metabolic bone diseases | D001851 | — | — | — | 1 | 1 | — | — | 2 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 2 | — | — | 4 | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | — | — | — | 2 |
| Myalgia | D063806 | — | M79.1 | 1 | 1 | — | — | — | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | 1 | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
| Vomiting | D014839 | — | R11.1 | — | 1 | — | — | — | 1 |
| Nausea | D009325 | — | R11.0 | — | 1 | — | — | — | 1 |
| Headache | D006261 | — | R51 | — | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 3 | 3 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 3 | 3 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 3 | 3 |
| Body weight changes | D001836 | — | — | — | — | — | — | 2 | 2 |
| Skin ulcer | D012883 | — | L98.4 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 2 | 2 |
| Varicose veins | D014648 | — | I83.90 | — | — | — | — | 2 | 2 |
| Exercise tolerance | D017079 | — | — | — | — | — | — | 2 | 2 |
| Vascular ring | D000073872 | — | Q25.45 | — | — | — | — | 1 | 1 |
| Weight gain | D015430 | — | — | — | — | — | — | 1 | 1 |
Show 34 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Diosmin |
| INN | diosmin |
| Description | Diosmin is a disaccharide derivative that consists of diosmetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. It has a role as an antioxidant and an anti-inflammatory agent. It is a glycosyloxyflavone, a rutinoside, a disaccharide derivative, a monomethoxyflavone and a dihydroxyflavanone. It is functionally related to a diosmetin. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O |
Identifiers
| PDB | — |
| CAS-ID | 520-27-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL231884 |
| ChEBI ID | 4631 |
| PubChem CID | 5281613 |
| DrugBank | DB08995 |
| UNII ID | 7QM776WJ5N (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,186 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
610 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use